A Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan - BBI-20231001

Bolt Biotherapeutics Inc.0 个研究点目标入组 70 人开始时间: 2023年8月25日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 70

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Be able to understand and sign the informed consent form., Adequate organ function defined as per protocol., Women of childbearing potential should agree not to donate eggs and must use a highly effective contraceptive measure (a method that can achieve a failure rate of less than 1% per year) during treatment and until 7 months after the end treatment. Highly effective, alternative non-hormonal contraceptive measures are preferred., Potent men that are partners of women of childbearing potential must be willing to use condoms in combination with a second highly effective method of female contraception (as above) during the study and agree not to donate sperm from Screening through 7 months after completion of study. A male partner will be considered as potent unless surgically sterilized (with documentation of sterility)., Be age 18 years or older at the time of informed consent., All subjects must agree to have a biopsy prior to enrollment. If, in the judgement of the Investigator, a biopsy is not safely accessible or clinically feasible an archival tumor tissue must be submitted in lieu of a freshly collected specimen., Histologically confirmed adenocarcinoma of the breast that is HER2+ (per 2018 ASCO/CAP HER2 testing guidelines) by Clinical Laboratory Improvement Amendments (CLIA) certified laboratory assessment, Have received 2 or more prior lines of anti- human epidermal growth factor receptor 2 (HER2)-directed therapies, at least 1 of them is in the metastatic setting and 1 of the prior therapies needs to be trastuzumab deruxtecan (ENHERTU®). Prior neo-adjuvant or adjuvant therapy that resulted in relapse within 12 months of completion of therapy will be considered a line of treatment for metastatic disease, Have experienced disease progression on or been otherwise unsuitable for (eg, did not tolerate) the most recent therapy, Have measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, Have expected life expectancy of greater than 12 weeks per the Investigator

排除标准

•Central nervous system metastases with the exception of disease that is asymptomatic, clinically stable (without evidence of progression for at least 4 weeks by repeating imaging during study Screening), and has not required steroids for at least 28 days before starting study treatment., Malignancy within 2 years before starting study treatment other than the disease under study. Exceptions include indolent or definitively treated disease not expected to require treatment during the study, affect the safety of subjects, or affect the endpoints of the trial, Any medical condition requiring corticosteroids (> 10 mg daily oral prednisone or equivalent) or other systemic immunosuppressive therapy within 28 days before starting study treatment. Exceptions include inhaled or topical steroids, Residual toxicity from previous treatment as described in the protocol, Prior anticancer therapies as described in protocol., History of severe hypersensitivity to any ingredient of BDC-1001 or pertuzumab, Received live/attenuated virus vaccine within 28 days before starting study treatment, Major surgery within 28 days of starting study treatment, Radiation therapy within 2 weeks of C1D1, Actively enrolled in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study, Subject is a lactating mother or pregnant as confirmed by pregnancy tests within 7 days prior to start of study treatment, Cardiac disease as described in the protocol., Subject is unwilling or unable to follow protocol requirements., Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage., Any condition that, in the opinion of the Investigator, would interfere with evaluation of BDC-1001 and pertuzumab or interpretation of the subject’s safety or study results, Pulmonary disease including idiopathic pulmonary fibrosis, interstitial lung disease, pneumonitis requiring steroids, or symptomatic pleural effusion within 6 months before starting study treatment OR ongoing requirement for supplemental oxygen, Hepatic disease resulting in symptomatic ascites, encephalopathy, coagulopathy, esophageal/gastric varices, or persistent jaundice, Arterial thrombotic event, stroke, or transient ischemia attack within 6 months before starting study treatment, Bleeding diathesis or uncontrolled bleeding within 7 days before starting study treatment, Bone marrow transplant or solid organ transplant, Infection included in the protocol., Autoimmune disease requiring systemic disease-modifying or immunosuppressive therapy within 2 years before starting study treatment. Exceptions include disease managed with only replacement therapies (eg, thyroxine, etc.)

研究者

发起方

Bolt Biotherapeutics Inc.

相似试验

进行中（未招募）

1 期

Study to investigate the function of three medicinal products (monoclonal antibodies) on a population of patients with colorectal cancer that has spread from its site of origin to another part of the body.Metastatic Colorectal Carcinoma

EUCTR2018-000618-39-ESSymphogen A/S54

进行中（未招募）

1 期

EUCTR2018-000618-39-ITSYMPHOGEN A/S54

已完成

不适用

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer-C539 Cervix uteri, unspecifiedCervix uteri, unspecifiedC539

PER-112-06GLAXOSMITHKLINE PERU S.A.,30

进行中（未招募）

1 期

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FIGO Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for Advanced/Recurrent DiseasePatients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent diseaseMedDRA version: 8.1 Level: LLT Classification code 10008229 Term: Cervical cancer

EUCTR2006-000236-27-FRGlaxoSmithKline Research & Development Limited

进行中（未招募）

不适用

EUCTR2006-000236-27-BEGlaxoSmithKline Research & Development Limited180